TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion
Open Access
- 10 May 2019
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 116 (21) , 10453-10462
Abstract
Significance: To overcome the challenge of nonresponsiveness or low effectiveness to current checkpoint blockade drugs, various combination therapies are under investigation for cancer treatment. In this study, we investigated a combination of Toll-like receptor 1/2 (TLR1/2) ligand and anti–CTLA-4 antibody in a mouse model of melanoma. TLR1/2 ligand enhanced the antitumor efficacy of anti–CTLA-4 by increasing Fcγ receptor IV expression, which in turn increased the depletion of tumor-infiltrating regulatory T cells. Whether ipilimumab causes Treg depletion in human patients is debatable; therefore, combining ipilimumab with Pam3CSK4 could lead to greater antitumor efficacy by introducing this modality. These findings are likely extensible to other checkpoint antibodies in cancer patients.Keywords
Funding Information
- Cancer Prevention and Research Institute of Texas (R1203)
- Gouvernement du Canada | Canadian Institutes of Health Research (86655)
This publication has 53 references indexed in Scilit:
- TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody TherapyClinical Cancer Research, 2011
- Protective and pathogenic functions of macrophage subsetsNature Reviews Immunology, 2011
- Amplifying TLR-MyD88 Signals within Tumor-Specific T Cells Enhances Antitumor Activity to Suboptimal Levels of Weakly Immunogenic Tumor AntigensCancer Research, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences, 2010
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodiesJournal of Experimental Medicine, 2009
- Engagement of Toll‐like receptor‐2 on cytotoxic T‐lymphocytes occurs in vivo and augments antitumor activityThe FASEB Journal, 2008
- CD4+CD25+Foxp3+regulatory T cells induce alternative activation of human monocytes/macrophagesProceedings of the National Academy of Sciences, 2007
- Toll-like receptor 2 signaling modulates the functions of CD4+CD25+regulatory T cellsProceedings of the National Academy of Sciences, 2006
- Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motilityNature Immunology, 2003